Authors:
Clarke-Pearson, DL
Van Le, L
Iveson, T
Whitney, CW
Hanjani, P
Kristensen, G
Malfetano, JH
Beckman, RA
Ross, GA
Lane, SR
DeWitte, MH
Fields, SZ
Citation: Dl. Clarke-pearson et al., Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer, J CL ONCOL, 19(19), 2001, pp. 3967-3975
Citation: A. Cesano et al., Stabilization of disease as an indicator of clinical benefit associated with chemotherapy in non-small cell lung cancer patients, INT J ONCOL, 17(3), 2000, pp. 587-590
Authors:
Cesano, A
Lane, SR
Poulin, R
Ross, G
Fields, SZ
Citation: A. Cesano et al., Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients, INT J ONCOL, 15(6), 1999, pp. 1233-1238
Authors:
von Pawel, J
Schiller, JH
Shepherd, FA
Fields, SZ
Kleisbauer, JP
Chrysson, NG
Stewart, DJ
Clark, PI
Palmer, MC
Depierre, A
Carmichael, J
Krebs, JB
Ross, G
Lane, SR
Gralla, R
Citation: J. Von Pawel et al., Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer, J CL ONCOL, 17(2), 1999, pp. 658-667